Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 19/20 | 1.00 |
| ▸ | CA1 | P00915 | 2/20 | 0.70 |
| ▸ | CA2 | P00918 | 2/20 | 0.70 |
| ▸ | CA9 | Q16790 | 2/20 | 0.70 |
| ▸ | ESR1 | P03372 | 1/20 | 0.70 |
| ▸ | CA4 | P22748 | 1/20 | 0.70 |
| ▸ | CA6 | P23280 | 1/20 | 0.70 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.70 |
| ▸ | SHBG | P04278 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3384071 | 1.00 | STS (1.00) | STSCA1CA2CA9ESR1 | |
| SCHEMBL8629445 | 0.89 | STS (0.80) | STSCA1CA2CA9ESR1 | |
| SCHEMBL8214022 | 0.86 | STS (0.76) | STSCA1CA2CA9ESR1 | |
| SCHEMBL23645588 | 0.85 | STS (0.74) | STSCA1CA2CA9ESR1 | |
| SCHEMBL2232239 | 0.85 | STS (0.74) | STSCA1CA2CA9ESR1 | |
| SCHEMBL2852317 | 0.84 | STS (0.73) | STSCA1CA2CA9ESR1 | |
| SCHEMBL14506049 | 0.83 | STS (0.77) | STSCA2CA9SHBG | |
| Emate SCHEMBL10062721 | 0.83 | STS (1.00) | STSCA1CA2CA9ESR1 | |
| Emate SCHEMBL14548146 | 0.83 | STS (1.00) | STSCA1CA2CA9ESR1 | |
| Emate SCHEMBL6370815 | 0.83 | STS (1.00) | STSCA1CA2CA9ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6583130-B1 | Substituted with acyl, oxycarbonyl, aminocarbonyl, sulfonyl, or aminosulfonyl; inhibit steroid sulfatase, do not exhibit any estrogenic effect and will not yield any estrogenic products on hydrolysis; treatment of estrogen-dependent tumors | SCHERING AG (DE) | 2003-06-24 | — | — | US | claimed |
| EP-0862577-B1 | SULPHAMATE DERIVATIVES OF 1,3,5(10)-ESTRATRIENE DERIVATIVES, METHODS OF PRODUCING THEM AND PHARMACEUTICAL COMPOUNDS CONTAINING THEM | JENAPHARM GMBH (DE) | 1999-04-14 | — | — | EP | claimed |
| US-5705495-A | STEROIDS WITH ESTROGENIC EFFECT | JENAPHARM GMBH & CO. KG. (DE) | 1998-01-06 | — | — | US | claimed |
| US-20260026497-A1 | SURFACE MODIFICATION OF BIODEGRADABLE POLYMERS AND USES THEREOF FOR RELEASE OF BIO-ACTIVE COMPOUNDS | CHOUINARD, Gérald (CA) | 2026-01-29 | — | — | US | disclosed |
| CN-119046155-A | Unit test method and device for multiplexing Spring containers for multiple times under Junit test framework | 杭州乒乓智能技术有限公司 | 2024-11-29 | — | — | CN | disclosed |
| WO-2024016086-A1 | SURFACE MODIFICATION OF BIODEGRADABLE POLYMERS AND USES THEREOF FOR RELEASE OF BIO-ACTIVE COMPOUNDS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2024-01-25 | — | — | WO | disclosed |
| EP-3980169-A1 | EMULSIONS OBTAINED BY A BIOSUSTAINABLE PROCESS | Prodotti Gianni S.r.l. (IT) | 2022-04-13 | — | — | EP | disclosed |
| EP-1599493-B1 | 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-YL SULFAMATE WITH AN ANTI-TUMOUR ACTION | STERIX LTD (GB) | 2010-11-24 | — | — | EP | disclosed |
| EP-1599493-B1 | 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-YL SULFAMATE WITH AN ANTI-TUMOUR ACTION | STERIX LTD (GB) | 2010-11-24 | — | — | EP | disclosed |
| US-20090221841-A1 | 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-YL SULFAMATE WITH AN ANTI-TUMOUR ACTION | STERIX LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20060160782-A1 | 2-Substituted estra-1,3,5(10)-triene-3-yl sulfamate with an anti-tumour action | STERIX LIMITED (GB) | 2006-07-20 | — | — | US | disclosed |
| EP-1599493-A1 | 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-YL SULFAMATE WITH AN ANTI-TUMOUR ACTION | Schering Aktiengesellschaft (DE) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004074307-A1 | 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-YL SULFAMATE WITH AN ANTI-TUMOUR ACTION | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-09-02 | — | — | WO | disclosed |
| US-6583130-B1 | Substituted with acyl, oxycarbonyl, aminocarbonyl, sulfonyl, or aminosulfonyl; inhibit steroid sulfatase, do not exhibit any estrogenic effect and will not yield any estrogenic products on hydrolysis; treatment of estrogen-dependent tumors | SCHERING AG (DE) | 2003-06-24 | — | — | US | disclosed |
| EP-1273590-A2 | Estra- 1,3,5(10)-triene Derivatives, Methods of Preparing Such Compounds and Pharmaceutical Compositions Containing Them | Jenapharm GmbH & Co. KG (DE) | 2003-01-08 | — | — | EP | disclosed |
| US-5705495-A | STEROIDS WITH ESTROGENIC EFFECT | JENAPHARM GMBH & CO. KG. (DE) | 1998-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160782-A1 | 2-Substituted estra-1,3,5(10)-triene-3-yl sulfamate with an anti-tumour action | SULT1E1, SULT1A1, SULT2A1 | STS 5/4885CA1 327/4885CA2 812/4885 |
| US-20260026497-A1 | SURFACE MODIFICATION OF BIODEGRADABLE POLYMERS AND USES THEREOF FOR RELEASE OF BIO-ACTIVE COMPOUNDS | PTMS, LRBA, SHBG | STS 773/4885CA1 822/4885CA2 3226/4885 |
| US-20090221841-A1 | 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-YL SULFAMATE WITH AN ANTI-TUMOUR ACTION | SULT1E1, SULT1A1, SULT2A1 | STS 5/4885CA1 333/4885CA2 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.